National Registry of IgG4-RD in China

This is a multicenter registry study of IgG4-RD patients. Newly diagnosed IgG4-RD patients will be recruited from allover the China. Inclusion criteria: patients with definite, probable, or possible IgG4-RD according to the 2011 comprehensive diagnostic criteria for IgG4-RD will be recruited. Exclusion criteria: patients with malignancy or other autoimmune diseases are excluded.

The data will be uploaded through the platform of Chinese Rheumatology Information Platform. Demographic data, initial symptoms, disease duration, history of allergy, and physical examination, organ involvements, laboratory findings, radiological and pathological results, as well as treatment, side effects will be recorded.

This study was approved by the Medical Ethics Committee of PUMCH (Beijing, China). All patients will signe informed consent.

Statistical Analysis: All parameters are described in the standard summary statistics, including mean, standard deviation, minimum, and maximum. All statistical analyses will be performed by SPSS.

Endpoints: The primary endpoint is to investigate the organ involvements of Chinese IgG4-RD patients. The secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.

• Response rate of glucocorticoids and immunosuppressants on IgG4-RD in China [Срок оценки: 5 years]
• Relapse rate of IgG4-RD patients in China [Срок оценки: 5 years]
• The correlation between baseline disease activities and relapse rate. [Срок оценки: 5 years]
• The incidence rate of tumor in IgG4 related disease patients in China. [Срок оценки: 5 years]
• Ten year survival rate of patients with IgG4 related disease in China. [Срок оценки: 10 years]
• The imaging features of involved organs. [Срок оценки: 3 years]
• The sensitivity and specificity of IgG4 positive plasma cells in pathological diagnosis of IgG4 related disease. [Срок оценки: 3 years]